Mainz Biomed (NASDAQ:MYNZ – Free Report)’s stock is scheduled to reverse split before the market opens on Tuesday, December 3rd. The 1-40 reverse split was announced on Friday, November 29th. The number of shares owned by shareholders will be adjusted after the market closes on Monday, December 2nd.
Mainz Biomed Trading Down 14.1 %
NASDAQ MYNZ traded down $0.04 on Friday, hitting $0.22. 7,094,717 shares of the stock traded hands, compared to its average volume of 1,350,238. The stock has a 50-day moving average of $0.26 and a 200 day moving average of $0.39. Mainz Biomed has a twelve month low of $0.19 and a twelve month high of $1.79.
Analysts Set New Price Targets
Separately, HC Wainwright lowered Mainz Biomed from a “buy” rating to a “neutral” rating in a research report on Monday.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Read More
- Five stocks we like better than Mainz Biomed
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- 3 Penny Stocks Ready to Break Out in 2025
- How to Plot Fibonacci Price Inflection Levels
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
